NCT01222780View on ClinicalTrials.gov

To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
SarcomaNeuroblastomaWilms TumorLeukemiaLymphomaBrain Tumors
Interventions
DRUG

Marqibo

Marqibo® intravenously (IV) over 60 minutes (+ 10 minutes) every 7 days (+ 3 days) for 4 consecutive weeks (day 1, 8, 15, 22) for a 28-day treatment cycle

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Acrotech Biopharma Inc.

INDUSTRY